ZA201903749B - Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome - Google Patents

Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome

Info

Publication number
ZA201903749B
ZA201903749B ZA2019/03749A ZA201903749A ZA201903749B ZA 201903749 B ZA201903749 B ZA 201903749B ZA 2019/03749 A ZA2019/03749 A ZA 2019/03749A ZA 201903749 A ZA201903749 A ZA 201903749A ZA 201903749 B ZA201903749 B ZA 201903749B
Authority
ZA
South Africa
Prior art keywords
alleviating
preventing
carbamate compound
tremor syndrome
treating tremors
Prior art date
Application number
ZA2019/03749A
Other languages
English (en)
Inventor
Jin Uk Yoo
Hye Sung Lee
Han Ju Yi
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of ZA201903749B publication Critical patent/ZA201903749B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA2019/03749A 2016-12-14 2019-06-11 Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome ZA201903749B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14
PCT/KR2017/014743 WO2018111009A1 (ko) 2016-12-14 2017-12-14 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (1)

Publication Number Publication Date
ZA201903749B true ZA201903749B (en) 2022-01-26

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2019/03749A ZA201903749B (en) 2016-12-14 2019-06-11 Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome

Country Status (13)

Country Link
US (1) US11033531B2 (https=)
EP (1) EP3556364B1 (https=)
JP (1) JP7086076B2 (https=)
KR (1) KR102635941B1 (https=)
CN (1) CN110267657B (https=)
AU (1) AU2017374459B2 (https=)
CL (1) CL2019001623A1 (https=)
ES (1) ES3039979T3 (https=)
IL (1) IL267191B2 (https=)
MX (1) MX391363B (https=)
MY (1) MY198417A (https=)
WO (1) WO2018111009A1 (https=)
ZA (1) ZA201903749B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711760B1 (en) * 2017-11-14 2024-02-14 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1411917E (pt) 2001-02-27 2007-09-17 Ortho Mcneil Pharm Inc ''compostos carbamatos para utilização na prevenção ou tratamento de distúrbios do movimento''
CN1938031A (zh) * 2004-03-29 2007-03-28 默克公司 作为钠通道阻滞剂的联芳取代的吡嗪酮类
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2008107909A1 (en) * 2007-03-05 2008-09-12 Indus Biotech Private Limited Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof
WO2010150946A1 (en) 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
KR102489052B1 (ko) 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
EP3556364A4 (en) 2020-06-17
WO2018111009A1 (ko) 2018-06-21
JP2020502137A (ja) 2020-01-23
KR20190087573A (ko) 2019-07-24
BR112019012000A2 (pt) 2019-10-29
US20190336481A1 (en) 2019-11-07
CA3046300A1 (en) 2018-06-21
AU2017374459A1 (en) 2019-07-04
AU2017374459B2 (en) 2023-04-27
CN110267657A (zh) 2019-09-20
JP7086076B2 (ja) 2022-06-17
MX2019006941A (es) 2019-09-06
IL267191B2 (en) 2023-05-01
RU2019121914A3 (https=) 2021-04-21
ES3039979T3 (en) 2025-10-28
KR102635941B1 (ko) 2024-02-13
EP3556364A1 (en) 2019-10-23
MY198417A (en) 2023-08-29
US11033531B2 (en) 2021-06-15
IL267191B1 (en) 2023-01-01
RU2019121914A (ru) 2021-01-15
MX391363B (es) 2025-03-21
CN110267657B (zh) 2022-12-13
CL2019001623A1 (es) 2019-08-23
IL267191A (https=) 2019-07-31
EP3556364B1 (en) 2025-08-27

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, preparations and methods for treating the disease
DK3658539T3 (da) Forbindelser og sammensætninger til behandling af tilstande, som er forbundet med nlrp-aktivitet
IL264156A (en) Compounds, preparations and methods for treating the disease
ZA201708039B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
SI3109223T1 (sl) Zmes za obdelavo gnojil, ki vsebujejo sečnino
WO2014165090A8 (en) Compounds for the treatment of tuberculosis
DK3624796T3 (da) Pyrrolopyridin.anilinforbindelser til behandling af hudlidelse
PT3519569T (pt) Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses
PL3065732T3 (pl) Związki, kompozycje i odpowiednie zastosowania do zapobiegania i/lub leczenia dyslipidemii
IL262825A (en) Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment
PL3384915T3 (pl) Karymycyna do leczenia zakażeń prątkiem gruźlicy
PL3459543T3 (pl) Związek karbaminianowy do zapobiegania lub leczenia fibromialgii
ZA201906047B (en) Compounds for treating tuberculosis
IL251456A0 (en) Substances with agonist activity for gpr119, processes for their preparation and preparations containing them
EP2982378A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF SEPSIS OR SEPTIC SHOCK WITH ADK PROTEIN AS AN ACTIVE SUBSTANCE
ZA201903749B (en) Use of carbamate compound for preventing, alleviating, or treating tremors or tremor syndrome
ZA201903747B (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
IL274428A (en) Use of a carbamate compound to prevent, relieve or treat a withdrawal seizure or epilepsy presenting with a withdrawal seizure
PT3459542T (pt) Utilização de composto carbamato para prevenção ou tratamento de neuralgia trigeminal
IL274084A (en) Comb for the treatment of dandruff
ZA201901948B (en) Heteroaryltrifluoroborate compounds for the treatment of mycobacterial infections
GB201614609D0 (en) Compounds for treatment of intractable epilepsy and doors syndrome
GB201701928D0 (en) Compounds for the treatment of hyperglycaemia
GB201603882D0 (en) Compounds for the treatment of type 2 diabetes
GB201603886D0 (en) Compounds for the treatment of type 2 diabetes